Anavex Pulls Alzheimer’s Drug Application in Europe After EMA Feedback
Anavex Life Sciences has withdrawn its EU marketing application for blarcamesine as an add-on therapy for early Alzheimer’s. Shares fell sharply after EMA committee feedback.
/ 3 items
#AVXL↓
Anavex Faces Setback in EU Alzheimer's Drug Review
Anavex Life Sciences receives negative EU opinion for blarcamesine Alzheimer's treatment but plans to request re-examination with new reviewers.
Anavex Faces Setback in European Alzheimer's Drug Approval
Anavex Life Sciences receives negative trend vote from EMA for blarcamesine Alzheimer's treatment but plans re-examination and continues FDA discussions.